Inflammatory Biomarkers as Predictors of Symptomatic Venous Thromboembolism in Hospitalized Patients with AECOPD: A Multicenter Cohort Study
Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE i...
Saved in:
Published in | Journal of Atherosclerosis and Thrombosis Vol. 32; no. 4; pp. 439 - 457 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
Japan Atherosclerosis Society
01.04.2025
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.Methods: A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.Results: Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.Conclusion: Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis. |
---|---|
AbstractList | Aim:
Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.
Methods:
A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.
Results:
Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (
p
all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.
Conclusion:
Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis. Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD. A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value. Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores. Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis. Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.AIMVenous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.METHODSA prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.RESULTSAmong the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis.CONCLUSIONEasily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis. Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.Methods: A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.Results: Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.Conclusion: Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis. |
ArticleNumber | 65177 |
Author | Chen, Xueqing Feng, Jiaming Zhang, Jianchu Yi, Mengqiu Zhou, Hui Li, Xianhua Zeng, Jiaxin Luo, Yuanming Ge, Huiqing Peng, Lige On behalf of the MAGNET AECOPD Registry Investigators Cheng, Lina Xie, XiuFang Liu, Huiguo Zhou, Haixia Zhang, Jiarui Yi, Qun Pu, Jiaqi Pan, Pinhua Wei, Hailong |
Author_xml | – sequence: 1 fullname: Zeng, Jiaxin organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University – sequence: 2 fullname: Feng, Jiaming organization: West China School of Medicine, West China Hospital, Sichuan University – sequence: 3 fullname: Luo, Yuanming organization: State Key Laboratory of Respiratory Disease, Guangzhou Medical University – sequence: 4 fullname: Wei, Hailong organization: Department of Respiratory and Critical Care Medicine, People's Hospital of Leshan – sequence: 5 fullname: Ge, Huiqing organization: Department of Respiratory and Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine – sequence: 6 fullname: Liu, Huiguo organization: Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 7 fullname: Zhang, Jianchu organization: Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 8 fullname: Li, Xianhua organization: Department of Respiratory and Critical Care Medicine, the First People's Hospital of Neijiang City – sequence: 9 fullname: Pan, Pinhua organization: Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University – sequence: 10 fullname: Xie, XiuFang organization: Department of Respiratory and Critical Care Medicine, the First People's Hospital of Neijiang City – sequence: 11 fullname: Yi, Mengqiu organization: Department of Emergency, First People's Hospital of Jiujiang – sequence: 12 fullname: Cheng, Lina organization: Department of Emergency, First People's Hospital of Jiujiang – sequence: 13 fullname: Zhou, Hui organization: Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Chengdu University – sequence: 14 fullname: Zhang, Jiarui organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University – sequence: 15 fullname: Peng, Lige organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University – sequence: 16 fullname: Pu, Jiaqi organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University – sequence: 17 fullname: Chen, Xueqing organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University – sequence: 18 fullname: Yi, Qun organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University – sequence: 19 fullname: Zhou, Haixia organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University – sequence: 20 fullname: On behalf of the MAGNET AECOPD Registry Investigators |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39477518$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkU1vEzEQhi1URD_gwB9APsIhZf2xtssFhVBopaJGauFq2d7ZrsPuOtheUPgN_GictAQ42B75ffzOeOYYHYxhBISek-q0rmvyemXyqaiJlI_QEVGqmjEl2UGJGS8xl-oQHae0qirG6po-QYfsjEtZE3WEfl2ObW-GweQQN_idD4OJXyEmbBJeRmi8K0LCocU3m2Gdi5y9w19gDFPCt10Mgw1QVu_TgP2IL0Ja-2x6_xMavCwwjDnhHz53eH6-uF6-f4Pn-NPUF5eiQMSL0IWY8U2ems1T9Lg1fYJnD-cJ-vzh_HZxMbu6_ni5mF_NHBdVnqkWGsKkcK2FChi1XBDaEMk5cdYoXm6FNZYyQoXgSrmKs5YUyNqWciPYCXp777ue7ADNtpJoer2Ovvx-o4Px-n9l9J2-C981IWeS1ZQXh5cPDjF8myBlPfjkoO_NCKUzuqSmgknGt-iLf5Pts_yZQQFe3QMuhpQitHuEVHo7X13mq3fz_Vv5KmVzB3vSxNLQHnYko5pvt92LveI6EzWM7Df94rHp |
Cites_doi | 10.3324/haematol.2016.142471 10.1093/jalm/jfab094 10.1002/ame2.12277 10.1016/j.ejim.2020.05.006 10.1186/s12879-024-09205-3 10.1186/s12890-024-02948-4 10.1111/crj.12959 10.7326/0003-4819-155-9-201111010-00008 10.1186/s12959-022-00381-3 10.1378/chest.11-2296 10.1016/j.amjmed.2015.10.027 10.1160/TH11-09-0611 10.1002/jhm.888 10.1159/000496914 10.1016/j.pupt.2006.04.004 10.1111/crj.12131 10.1055/a-1693-0063 10.2147/JIR.S327014 10.3233/CH-221664 10.1016/j.ijbiomac.2021.06.140 10.1177/10760296221130061 10.3390/ph16091254 10.1378/chest.06-2993 10.1097/MJT.0b013e31826910dd 10.1046/j.1365-2141.2001.03061.x 10.1159/000335904 10.1055/s-0042-1748193 10.3390/jcm10102061 10.1186/s40364-020-00207-2 10.1111/j.1538-7836.2007.02468.x 10.1111/aor.12943 10.4187/respcare.06661 10.3389/fimmu.2018.01351 10.1164/rccm.202301-0106PP 10.2147/COPD.S410954 10.1590/S1806-37132014000100006 10.1016/j.thromres.2003.12.003 10.1001/jama.2020.23567 10.2147/COPD.S396311 10.1007/PL00000237 10.1182/blood.2019004781 10.1378/chest.10-1944 10.1111/j.1538-7836.2010.04044.x 10.1016/j.jvsv.2022.05.003 10.1038/s41598-020-65128-4 10.1016/S0140-6736(08)60202-0 10.17219/acem/76262 10.1016/j.chest.2018.09.020 |
ContentType | Journal Article |
Copyright | This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. 2025 Japan Atherosclerosis Society 2025 |
Copyright_xml | – notice: This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. – notice: 2025 Japan Atherosclerosis Society 2025 |
CorporateAuthor | On behalf of the MAGNET AECOPD Registry Investigators MAGNET AECOPD Registry Investigators |
CorporateAuthor_xml | – name: On behalf of the MAGNET AECOPD Registry Investigators – name: MAGNET AECOPD Registry Investigators |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.5551/jat.65177 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1880-3873 |
EndPage | 457 |
ExternalDocumentID | PMC11973524 39477518 10_5551_jat_65177 article_jat_32_4_32_65177_article_char_en |
Genre | Multicenter Study Journal Article |
GroupedDBID | --- .55 29J 2WC 53G 5GY 5VS ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK DU5 E3Z F5P GX1 HYE JMI JSF JSH KQ8 OK1 P6G RJT RNS RPM RZJ TR2 X7M AAFWJ AAYXX CITATION OVT CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c460t-8fed1376cfbe0e32b4612d17441cba84be06bab231266488c043f1461bbf24a63 |
ISSN | 1340-3478 1880-3873 |
IngestDate | Thu Aug 21 18:37:08 EDT 2025 Fri Jul 11 16:11:56 EDT 2025 Wed Jul 02 01:57:09 EDT 2025 Tue Jul 01 05:14:00 EDT 2025 Thu May 08 13:50:29 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 4 |
Keywords | Inflammatory biomarkers Acute exacerbation of chronic obstructive pulmonary disease Venous thromboembolism |
Language | English |
License | This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c460t-8fed1376cfbe0e32b4612d17441cba84be06bab231266488c043f1461bbf24a63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 On behalf of the MAGNET AECOPD Registry Investigators |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11973524 |
PMID | 39477518 |
PQID | 3122637344 |
PQPubID | 23479 |
PageCount | 19 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11973524 proquest_miscellaneous_3122637344 pubmed_primary_39477518 crossref_primary_10_5551_jat_65177 jstage_primary_article_jat_32_4_32_65177_article_char_en |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-Apr-01 |
PublicationDateYYYYMMDD | 2025-04-01 |
PublicationDate_xml | – month: 04 year: 2025 text: 2025-Apr-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | Journal of Atherosclerosis and Thrombosis |
PublicationTitleAlternate | JAT |
PublicationYear | 2025 |
Publisher | Japan Atherosclerosis Society |
Publisher_xml | – name: Japan Atherosclerosis Society |
References | 29) Ristić L, Rančić M, Radović M, Cirić Z, Kutlešić Kurtović D: Pulmonary embolism in chronic hypoxemic patients with and without secondary polycythemia--analysis of risk factors in prospective clinical study. Med Glas (Zenica), 2013; 10: 258-265 18) Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA, Jr.: Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, 2008; 371: 387-394 22) Couturaud F, Bertoletti L, Pastre J, Roy PM, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Sanchez O, De Magalhaes E, Kamara M, Hoffmann C, Bressollette L, Nonent M, Tromeur C, Salaun PY, Barillot S, Gatineau F, Mismetti P, Girard P, Lacut K, Lemarié CA, Meyer G, Leroyer C: Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA, 2021; 325: 59-68 33) Liu X, Jiao X, Gong X, Nie Q, Li Y, Zhen G, Cheng M, He J, Yuan Y, Yang Y: Prevalence, Risk Factor and Clinical Characteristics of Venous Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective Multicenter Study. Int J Chron Obstruct Pulmon Dis, 2023; 18: 907-917 36) Tichelaar YI, Kluin-Nelemans HJ, Meijer K: Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost, 2012; 107: 827-837 20) Brown RA, Allegra L, Matera MG, Page CP, Cazzola M: Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther, 2006; 19: 419-424 34) Righini M: Is it worth diagnosing and treating distal deep vein thrombosis? No. J Thromb Haemost, 2007; 5 Suppl 1: 55-59 4) Keramidas G, Gourgoulianis KI, Kotsiou OS: Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns. J Clin Med, 2021; 10 25) Bahloul M, Chaari A, Tounsi A, Baccouche N, Abid H, Chtara K, Ben Hamida C, Ghadhoune H, Dammak H, Chelly H, Bouaziz M: Incidence and impact outcome of pulmonary embolism in critically ill patients with severe exacerbation of chronic obstructive pulmonary diseases. Clin Respir J, 2015; 9: 270-277 7) Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K, Fareed J, Antic D: Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J, 2022; 20: 20 19) Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E: Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. Am J Ther, 2013; 20: 132-142 39) Liu H, Guo N, Zheng Q, Zhang Q, Chen J, Cai Y, Luo Q, Xu Q, Chen X, Yang S, Zhang S: Association of interleukin-6, ferritin, and lactate dehydrogenase with venous thromboembolism in COVID-19: a systematic review and meta-analysis. BMC Infect Dis, 2024; 24: 324 41) McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, Peter K: Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes. Front Immunol, 2018; 9: 1351 26) Akpinar EE, Hoşgün D, Akpinar S, Ataç GK, Doğanay B, Gülhan M: Incidence of pulmonary embolism during COPD exacerbation. J Bras Pneumol, 2014; 40: 38-45 30) Lederle FA, Zylla D, MacDonald R, Wilt TJ: Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med, 2011; 155: 602-615 6) Xue J, Ma D, Jiang J, Liu Y: Diagnostic and Prognostic Value of Immune/Inflammation Biomarkers for Venous Thromboembolism: Is It Reliable for Clinical Practice? J Inflamm Res, 2021; 14: 5059-5077 45) Xu WJ, Wang S, Yuan P, Wang L, Huang JX, Jiang R: Arterial and venous thromboembolism risk associated with blood eosinophils: A systematic review and meta-analysis. Animal Model Exp Med, 2022; 5: 470-481 35) Kerr R, Stirling D, Ludlam CA: Interleukin 6 and haemostasis. Br J Haematol, 2001; 115: 3-12 1) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018; 392: 1736-1788 49) Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH: Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141: e195S-e226S 40) Li D, Wu Q, Liu S, Chen Y, Chen H, Ruan Y, Zhang Y: Lactic Dehydrogenase in the In Vitro Evaluation of Hemolytic Properties of Ventricular Assist Device. Artif Organs, 2017; 41: E274-e284 31) Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA: Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med, 2016; 129: 528-535 10) Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O: Serum albumin levels and inflammation. Int J Biol Macromol, 2021; 184: 857-862 27) Dentali F, Pomero F, Micco PD, La Regina M, Landini F, Mumoli N, Pieralli F, Giorgi-Pierfranceschi M, Re R, Vitale J, Fabbri LM, Fontanella A, Arioli D: Prevalence and risk factors for pulmonary embolism in patients with suspected acute exacerbation of COPD: a multi-center study. Eur J Intern Med, 2020; 80: 54-59 44) Wypasek E, Padjas A, Szymańska M, Plens K, Siedlar M, Undas A: Non-classical and intermediate monocytes in patients following venous thromboembolism: Links with inflammation. Adv Clin Exp Med, 2019; 28: 51-58 8) Hojker M, Tršan J, Tršan U, Gale A, Jerman A, Košuta D: Predictive value of inflammatory and coagulation biomarkers for venous thromboembolism in COVID-19 patients. Clin Hemorheol Microcirc, 2023; 83: 387-395 2) Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, López Varela MV, Wedzicha JA, Vogelmeier CF: Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med, 2023; 207: 819-837 48) Feng K, Wang K, Zhou Y, Xue H, Wang F, Jin H, Zhao W: Non-Anticoagulant Activities of Low Molecular Weight Heparins-A Review. Pharmaceuticals (Basel), 2023; 16 13) Zhang J, Yi Q, Zhou C, Luo Y, Wei H, Ge H, Liu H, Zhang J, Li X, Xie X, Pan P, Yi M, Cheng L, Zhou H, Liu L, Aili A, Liu Y, Peng L, Pu J, Zhou H: Characteristics, treatments, in-hospital and long-term outcomes among inpatients with acute exacerbation of chronic obstructive pulmonary disease in China: sex differences in a large cohort study. BMC Pulm Med, 2024; 24: 125 17) Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA, Jr.: Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest, 2007; 132: 936-945 37) Pfeiler S, Stark K, Massberg S, Engelmann B: Propagation of thrombosis by neutrophils and extracellular nucleosome networks. Haematologica, 2017; 102: 206-213 28) Choi KJ, Cha SI, Shin KM, Lee J, Hwangbo Y, Yoo SS, Lee J, Lee SY, Kim CH, Park JY, Jung TH: Prevalence and predictors of pulmonary embolism in Korean patients with exacerbation of chronic obstructive pulmonary disease. Respiration, 2013; 85: 203-209 12) Zhou C, Yi Q, Ge H, Wei H, Liu H, Zhang J, Luo Y, Pan P, Zhang J, Peng L, Aili A, Liu Y, Wang M, Tang Y, Wang L, Zhong X, Wang Y, Zhou H: Validation of Risk Assessment Models Predicting Venous Thromboembolism in Inpatients with Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: A Multicenter Cohort Study in China. Thromb Haemost, 2022; 122: 1177-1185 47) Wan MX, Zhang XW, Törkvist L, Thorlacius H: Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm Res, 2001; 50: 581-584 50) Thachil J, Favaloro EJ, Lippi G: D-dimers-"Normal" Levels versus Elevated Levels Due to a Range of Conditions, including "D-dimeritis," Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. Semin Thromb Hemost, 2022; 48: 672-679 16) Zhai Z, Kan Q, Li W, Qin X, Qu J, Shi Y, Xu R, Xu Y, Zhang Z, Wang C: VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study. Chest, 2019; 155: 114-122 46) Pu J, Yi Q, Luo Y, Wei H, Ge H, Liu H, Li X, Zhang J, Pan P, Zhou H, Zhou C, Yi M, Cheng L, Liu L, Zhang J, Peng L, Aili A, Liu Y, Zhou H: Blood Eosinophils and Clinical Outcomes in Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. Int J Chron Obstruct Pulmon Dis, 2023; 18: 169-179 3) Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RF: Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res, 2003; 112: 203-207 38) Hu J, Cai Z, Zhou Y: The Association of Neutrophil-Lymphocyte Ratio with Venous Thromboembolism: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost, 2022; 28: 10760296221130061 42) Heerink JS, Gemen E, Oudega R, Geersing GJ, Hopstaken R, Kusters R: Performance of C-Reactive Protein, Procalcitonin, TAT Complex, and Factor VIII in Addition to D-Dimer in the Exclusion of Venous Thromboembolism in Primary Care Patients. J Appl Lab Med, 2022; 7: 444-455 11) Elmoamly S, Mattar M, Yacoub MF, Afif A: Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies? Acta Haemat 44 45 46 47 48 49 50 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
References_xml | – reference: 49) Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH: Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141: e195S-e226S – reference: 27) Dentali F, Pomero F, Micco PD, La Regina M, Landini F, Mumoli N, Pieralli F, Giorgi-Pierfranceschi M, Re R, Vitale J, Fabbri LM, Fontanella A, Arioli D: Prevalence and risk factors for pulmonary embolism in patients with suspected acute exacerbation of COPD: a multi-center study. Eur J Intern Med, 2020; 80: 54-59 – reference: 38) Hu J, Cai Z, Zhou Y: The Association of Neutrophil-Lymphocyte Ratio with Venous Thromboembolism: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost, 2022; 28: 10760296221130061 – reference: 33) Liu X, Jiao X, Gong X, Nie Q, Li Y, Zhen G, Cheng M, He J, Yuan Y, Yang Y: Prevalence, Risk Factor and Clinical Characteristics of Venous Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective Multicenter Study. Int J Chron Obstruct Pulmon Dis, 2023; 18: 907-917 – reference: 50) Thachil J, Favaloro EJ, Lippi G: D-dimers-"Normal" Levels versus Elevated Levels Due to a Range of Conditions, including "D-dimeritis," Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. Semin Thromb Hemost, 2022; 48: 672-679 – reference: 30) Lederle FA, Zylla D, MacDonald R, Wilt TJ: Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med, 2011; 155: 602-615 – reference: 44) Wypasek E, Padjas A, Szymańska M, Plens K, Siedlar M, Undas A: Non-classical and intermediate monocytes in patients following venous thromboembolism: Links with inflammation. Adv Clin Exp Med, 2019; 28: 51-58 – reference: 14) Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P: A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost, 2010; 8: 2450-2457 – reference: 17) Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA, Jr.: Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest, 2007; 132: 936-945 – reference: 46) Pu J, Yi Q, Luo Y, Wei H, Ge H, Liu H, Li X, Zhang J, Pan P, Zhou H, Zhou C, Yi M, Cheng L, Liu L, Zhang J, Peng L, Aili A, Liu Y, Zhou H: Blood Eosinophils and Clinical Outcomes in Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. Int J Chron Obstruct Pulmon Dis, 2023; 18: 169-179 – reference: 5) Chen Y, Zhong H, Zhao Y, Luo X, Gao W: Role of platelet biomarkers in inflammatory response. Biomark Res, 2020; 8: 28 – reference: 4) Keramidas G, Gourgoulianis KI, Kotsiou OS: Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns. J Clin Med, 2021; 10: – reference: 11) Elmoamly S, Mattar M, Yacoub MF, Afif A: Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies? Acta Haematol, 2019; 141: 245-253 – reference: 32) Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP: Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med, 2011; 6: 202-209 – reference: 24) Pang H, Wang L, Liu J, Wang S, Yang Y, Yang T, Wang C: The prevalence and risk factors of venous thromboembolism in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J, 2018; 12: 2573-2580 – reference: 19) Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E: Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. Am J Ther, 2013; 20: 132-142 – reference: 12) Zhou C, Yi Q, Ge H, Wei H, Liu H, Zhang J, Luo Y, Pan P, Zhang J, Peng L, Aili A, Liu Y, Wang M, Tang Y, Wang L, Zhong X, Wang Y, Zhou H: Validation of Risk Assessment Models Predicting Venous Thromboembolism in Inpatients with Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: A Multicenter Cohort Study in China. Thromb Haemost, 2022; 122: 1177-1185 – reference: 8) Hojker M, Tršan J, Tršan U, Gale A, Jerman A, Košuta D: Predictive value of inflammatory and coagulation biomarkers for venous thromboembolism in COVID-19 patients. Clin Hemorheol Microcirc, 2023; 83: 387-395 – reference: 35) Kerr R, Stirling D, Ludlam CA: Interleukin 6 and haemostasis. Br J Haematol, 2001; 115: 3-12 – reference: 7) Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K, Fareed J, Antic D: Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J, 2022; 20: 20 – reference: 3) Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RF: Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res, 2003; 112: 203-207 – reference: 42) Heerink JS, Gemen E, Oudega R, Geersing GJ, Hopstaken R, Kusters R: Performance of C-Reactive Protein, Procalcitonin, TAT Complex, and Factor VIII in Addition to D-Dimer in the Exclusion of Venous Thromboembolism in Primary Care Patients. J Appl Lab Med, 2022; 7: 444-455 – reference: 1) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018; 392: 1736-1788 – reference: 2) Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, López Varela MV, Wedzicha JA, Vogelmeier CF: Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med, 2023; 207: 819-837 – reference: 25) Bahloul M, Chaari A, Tounsi A, Baccouche N, Abid H, Chtara K, Ben Hamida C, Ghadhoune H, Dammak H, Chelly H, Bouaziz M: Incidence and impact outcome of pulmonary embolism in critically ill patients with severe exacerbation of chronic obstructive pulmonary diseases. Clin Respir J, 2015; 9: 270-277 – reference: 34) Righini M: Is it worth diagnosing and treating distal deep vein thrombosis? No. J Thromb Haemost, 2007; 5 Suppl 1: 55-59 – reference: 9) Maners J, Gill D, Pankratz N, Laffan MA, Wolberg AS, de Maat MPM, Ligthart S, Tang W, Ward-Caviness CK, Fornage M, Debette S, Dichgans M, McKnight B, Boerwinkle E, Smith NL, Morrison AC, Dehghan A, de Vries PS: A Mendelian randomization of γ’ and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke. Blood, 2020; 136: 3062-3069 – reference: 6) Xue J, Ma D, Jiang J, Liu Y: Diagnostic and Prognostic Value of Immune/Inflammation Biomarkers for Venous Thromboembolism: Is It Reliable for Clinical Practice? J Inflamm Res, 2021; 14: 5059-5077 – reference: 16) Zhai Z, Kan Q, Li W, Qin X, Qu J, Shi Y, Xu R, Xu Y, Zhang Z, Wang C: VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study. Chest, 2019; 155: 114-122 – reference: 31) Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA: Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med, 2016; 129: 528-535 – reference: 23) Hassen MF, Tilouche N, Jaoued O, Elatrous S: Incidence and Impact of Pulmonary Embolism During Severe COPD Exacerbation. Respir Care, 2019; 64: 1531-1536 – reference: 29) Ristić L, Rančić M, Radović M, Cirić Z, Kutlešić Kurtović D: Pulmonary embolism in chronic hypoxemic patients with and without secondary polycythemia--analysis of risk factors in prospective clinical study. Med Glas (Zenica), 2013; 10: 258-265 – reference: 41) McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, Peter K: Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes. Front Immunol, 2018; 9: 1351 – reference: 26) Akpinar EE, Hoşgün D, Akpinar S, Ataç GK, Doğanay B, Gülhan M: Incidence of pulmonary embolism during COPD exacerbation. J Bras Pneumol, 2014; 40: 38-45 – reference: 20) Brown RA, Allegra L, Matera MG, Page CP, Cazzola M: Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther, 2006; 19: 419-424 – reference: 48) Feng K, Wang K, Zhou Y, Xue H, Wang F, Jin H, Zhao W: Non-Anticoagulant Activities of Low Molecular Weight Heparins-A Review. Pharmaceuticals (Basel), 2023; 16: – reference: 39) Liu H, Guo N, Zheng Q, Zhang Q, Chen J, Cai Y, Luo Q, Xu Q, Chen X, Yang S, Zhang S: Association of interleukin-6, ferritin, and lactate dehydrogenase with venous thromboembolism in COVID-19: a systematic review and meta-analysis. BMC Infect Dis, 2024; 24: 324 – reference: 15) Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AGG, Nakamura M, Piovella F, Kakkar AK, Spencer FA; IMPROVE Investigators: Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest, 2011; 140: 706-714 – reference: 43) Liu Y, Meng X, Feng J, Zhou X, Zhu H: Hypereosinophilia with Concurrent Venous Thromboembolism: Clinical Features, Potential Risk Factors, and Short-term Outcomes in a Chinese Cohort. Sci Rep, 2020; 10: 8359 – reference: 22) Couturaud F, Bertoletti L, Pastre J, Roy PM, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Sanchez O, De Magalhaes E, Kamara M, Hoffmann C, Bressollette L, Nonent M, Tromeur C, Salaun PY, Barillot S, Gatineau F, Mismetti P, Girard P, Lacut K, Lemarié CA, Meyer G, Leroyer C: Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA, 2021; 325: 59-68 – reference: 40) Li D, Wu Q, Liu S, Chen Y, Chen H, Ruan Y, Zhang Y: Lactic Dehydrogenase in the In Vitro Evaluation of Hemolytic Properties of Ventricular Assist Device. Artif Organs, 2017; 41: E274-e284 – reference: 28) Choi KJ, Cha SI, Shin KM, Lee J, Hwangbo Y, Yoo SS, Lee J, Lee SY, Kim CH, Park JY, Jung TH: Prevalence and predictors of pulmonary embolism in Korean patients with exacerbation of chronic obstructive pulmonary disease. Respiration, 2013; 85: 203-209 – reference: 10) Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O: Serum albumin levels and inflammation. Int J Biol Macromol, 2021; 184: 857-862 – reference: 13) Zhang J, Yi Q, Zhou C, Luo Y, Wei H, Ge H, Liu H, Zhang J, Li X, Xie X, Pan P, Yi M, Cheng L, Zhou H, Liu L, Aili A, Liu Y, Peng L, Pu J, Zhou H: Characteristics, treatments, in-hospital and long-term outcomes among inpatients with acute exacerbation of chronic obstructive pulmonary disease in China: sex differences in a large cohort study. BMC Pulm Med, 2024; 24: 125 – reference: 18) Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA, Jr.: Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, 2008; 371: 387-394 – reference: 21) Hayssen H, Cires-Drouet R, Englum B, Nguyen P, Sahoo S, Mayorga-Carlin M, Siddiqui T, Turner D, Yesha Y, Sorkin JD, Lal BK: Systematic review of venous thromboembolism risk categories derived from Caprini score. J Vasc Surg Venous Lymphat Disord, 2022; 10: 1401-1409.e1407 – reference: 47) Wan MX, Zhang XW, Törkvist L, Thorlacius H: Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm Res, 2001; 50: 581-584 – reference: 45) Xu WJ, Wang S, Yuan P, Wang L, Huang JX, Jiang R: Arterial and venous thromboembolism risk associated with blood eosinophils: A systematic review and meta-analysis. Animal Model Exp Med, 2022; 5: 470-481 – reference: 36) Tichelaar YI, Kluin-Nelemans HJ, Meijer K: Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost, 2012; 107: 827-837 – reference: 37) Pfeiler S, Stark K, Massberg S, Engelmann B: Propagation of thrombosis by neutrophils and extracellular nucleosome networks. Haematologica, 2017; 102: 206-213 – ident: 37 doi: 10.3324/haematol.2016.142471 – ident: 42 doi: 10.1093/jalm/jfab094 – ident: 45 doi: 10.1002/ame2.12277 – ident: 27 doi: 10.1016/j.ejim.2020.05.006 – ident: 39 doi: 10.1186/s12879-024-09205-3 – ident: 13 doi: 10.1186/s12890-024-02948-4 – ident: 24 doi: 10.1111/crj.12959 – ident: 30 doi: 10.7326/0003-4819-155-9-201111010-00008 – ident: 7 doi: 10.1186/s12959-022-00381-3 – ident: 49 doi: 10.1378/chest.11-2296 – ident: 31 doi: 10.1016/j.amjmed.2015.10.027 – ident: 36 doi: 10.1160/TH11-09-0611 – ident: 32 doi: 10.1002/jhm.888 – ident: 11 doi: 10.1159/000496914 – ident: 1 – ident: 20 doi: 10.1016/j.pupt.2006.04.004 – ident: 25 doi: 10.1111/crj.12131 – ident: 12 doi: 10.1055/a-1693-0063 – ident: 6 doi: 10.2147/JIR.S327014 – ident: 8 doi: 10.3233/CH-221664 – ident: 10 doi: 10.1016/j.ijbiomac.2021.06.140 – ident: 38 doi: 10.1177/10760296221130061 – ident: 48 doi: 10.3390/ph16091254 – ident: 17 doi: 10.1378/chest.06-2993 – ident: 19 doi: 10.1097/MJT.0b013e31826910dd – ident: 35 doi: 10.1046/j.1365-2141.2001.03061.x – ident: 28 doi: 10.1159/000335904 – ident: 50 doi: 10.1055/s-0042-1748193 – ident: 4 doi: 10.3390/jcm10102061 – ident: 5 doi: 10.1186/s40364-020-00207-2 – ident: 34 doi: 10.1111/j.1538-7836.2007.02468.x – ident: 40 doi: 10.1111/aor.12943 – ident: 23 doi: 10.4187/respcare.06661 – ident: 41 doi: 10.3389/fimmu.2018.01351 – ident: 2 doi: 10.1164/rccm.202301-0106PP – ident: 33 doi: 10.2147/COPD.S410954 – ident: 26 doi: 10.1590/S1806-37132014000100006 – ident: 3 doi: 10.1016/j.thromres.2003.12.003 – ident: 22 doi: 10.1001/jama.2020.23567 – ident: 46 doi: 10.2147/COPD.S396311 – ident: 47 doi: 10.1007/PL00000237 – ident: 9 doi: 10.1182/blood.2019004781 – ident: 15 doi: 10.1378/chest.10-1944 – ident: 29 – ident: 14 doi: 10.1111/j.1538-7836.2010.04044.x – ident: 21 doi: 10.1016/j.jvsv.2022.05.003 – ident: 43 doi: 10.1038/s41598-020-65128-4 – ident: 18 doi: 10.1016/S0140-6736(08)60202-0 – ident: 44 doi: 10.17219/acem/76262 – ident: 16 doi: 10.1016/j.chest.2018.09.020 |
SSID | ssj0033552 |
Score | 2.4027667 |
Snippet | Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which... Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is... Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which... |
SourceID | pubmedcentral proquest pubmed crossref jstage |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 439 |
SubjectTerms | Acute exacerbation of chronic obstructive pulmonary disease Aged Biomarkers - blood C-Reactive Protein - analysis Female Follow-Up Studies Hospitalization Humans Inflammation - blood Inflammatory biomarkers Male Middle Aged Neutrophils Original Prognosis Prospective Studies Pulmonary Disease, Chronic Obstructive - blood Pulmonary Disease, Chronic Obstructive - complications Risk Factors Venous thromboembolism Venous Thromboembolism - blood Venous Thromboembolism - diagnosis Venous Thromboembolism - epidemiology Venous Thromboembolism - etiology |
Title | Inflammatory Biomarkers as Predictors of Symptomatic Venous Thromboembolism in Hospitalized Patients with AECOPD: A Multicenter Cohort Study |
URI | https://www.jstage.jst.go.jp/article/jat/32/4/32_65177/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/39477518 https://www.proquest.com/docview/3122637344 https://pubmed.ncbi.nlm.nih.gov/PMC11973524 |
Volume | 32 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Atherosclerosis and Thrombosis, 2025/04/01, Vol.32(4), pp.439-457 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKglZ7WfFcygIyiBtKaWM3abmVssuCVOihC4VLFDsODdokVZtKsL-Bf8kfYcZ2Hq32AHuoVU3dOM18nRl7XoS8cKO4x9Rw6MgojhzuqYET-oI7ceQDfoTrR9pjOvnonZ3zD_P-vNX604ha2hSiIy-vzCu5DleBBnzFLNn_4Gx1USDAe-AvjMBhGP-Jx--zGBiaGkf5myRPMdZmtcbeMdMVemB0Kx1MS_mVLovcVGf9bKqyzharPBW5gtcFNsrAmle2h0hyCVbo1BRctdlvo5Pxp-lbk8auc3YxqFOtQJwswH7X0Yhb_uGGnatNzHwNtw5jsrYhm3rxdVJZ9N-UDQ1Owp9JBdjTmpqWOhajhzb6gPfrJsya5C_KtOAOk4vcUu15httvhMFoXQM2QvZytHNrNoS1IagZB_3BTfufjjI0kEVYK5g1pXt9elofXWhRzU0RJav1uSmTvatQ-mBQ6kYGRcfr9_ytOfDMl6lGFhtyH91XtU6tIh2nkzE6asHM5TfITRf2Mthm4928ikNiYPBpl3z5g0z5K1z4VbXsAdkv19iyn279gC3Ed3XV7mg3yLdhNc1uk0MLAzoy2L1DWiq7S_YnNqDjHvndhDCtIUzDNa0hTPOYNiBMDYTpDoRpktEmhGkJYYoQpgbCr-mINgBMDYCpBvB9cn56MhufObZBiCO51y2cQayiHmhIGQvVVSBaONjrEeyxeU-KcMCB6olQwBYGzFDQVLLLWYyN7IWIXR567AHZy_JMPSSUARykC7trzOwWDI8huBxK1mdhPJChbJPn5WMPlqYOTAD7Z2RTAGwKNJvaZGAYUk2xokFPYW7AcdBTq08wuRJkWZs8K1kYgIBHr12YKXiWAdy86zGfcd4mR4al1eVLUMDCW8yuJmDx-O1PsmShi8iXqHx0_a8ek4P6D_yY7BWrjXoCJnohnmqI_wVaifMR |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inflammatory+Biomarkers+as+Predictors+of+Symptomatic+Venous+Thromboembolism+in+Hospitalized+Patients+with+AECOPD%3A+A+Multicenter+Cohort+Study&rft.jtitle=Journal+of+atherosclerosis+and+thrombosis&rft.au=Zeng%2C+Jiaxin&rft.au=Feng%2C+Jiaming&rft.au=Luo%2C+Yuanming&rft.au=Wei%2C+Hailong&rft.date=2025-04-01&rft.pub=Japan+Atherosclerosis+Society&rft.issn=1340-3478&rft.eissn=1880-3873&rft.volume=32&rft.issue=4&rft.spage=439&rft.epage=457&rft_id=info:doi/10.5551%2Fjat.65177&rft_id=info%3Apmid%2F39477518&rft.externalDocID=PMC11973524 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-3478&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-3478&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-3478&client=summon |